GlassScriptPhysician profile
Latorya D Moore
NPI 1720593908
$4,597.03
in general payments reported to CMS, 2019-2025
17 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.42 · 2022: $30.53 · 2023: $3,700 · 2024: $308 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,700 · Food and Beverage: $664 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,700.00 |
| Food and Beverage | $663.88 |
| Education | $139.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,762.65 | 2023-2024 | |
| Janssen Biotech, INC. | $124.30 | 2021-2025 | Erleada, Rybrevant |
| Celgene Corporation | $107.79 | 2021-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $104.79 | 2025 | Enhertu, Lynparza |
| Gilead Sciences, INC. | $95.95 | 2025 | Trodelvy |
| Sobi, INC | $73.64 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $66.23 | 2025 | Opdivo |
| Glaxosmithkline, LLC. | $47.74 | 2024 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $44.35 | 2024-2025 | Xospata |
| Merck Sharp & Dohme LLC | $32.61 | 2025 | Welireg, Keytruda |
| Daiichi Sankyo INC. | $25.12 | 2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $24.01 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $21.76 | 2021 | |
| Eisai INC. | $19.19 | 2025 | |
| Eusa Pharma (US) LLC | $18.53 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $16.37 | 2024 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latorya Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.